(CercleFinance.com) – Sanofi announces the conclusion of a co-exclusive licensing agreement with Novavax, for the co-marketing of a Covid-19 vaccine and the development of combined influenza-Covid-19 vaccines, as well as a acquisition of a minority stake of less than 5% in Novavax.
As part of this, Novavax will receive an upfront payment of $500 million, up to $700 million depending on the achievement of various milestones, and double-digit tiered royalties on sales of Covid-19 and Covid-19 flu vaccines. made by Sanofi.
Novavax will also be entitled to payments of up to $200 million, as well as single-digit royalties for each additional Sanofi vaccine developed under non-exclusive license with Novavax’s Matrix-M adjuvant technology.
‘Apart from this collaboration, each party will be able to develop and market, at its own expense, its own vaccines against influenza and Covid-19, as well as its own adjuvanted products,’ specifies the French health group.